All In Biotech

Drug Trial Radar · NCT05109650

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6026 as Monotherapy and in Combination With BAT1308 in Patients With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

Feb 28, 2022

Primary completion

Mar 23, 2023

Study completion Feb 2, 2024

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase 1 dose-escalation study of BAT6026, an OX40 monoclonal antibody, combined with the anti-PD-1 IgG4 monoclonal antibody BAT1308 in subjects with advanced solid tumours. After a screening period of up to 28 days, qualified subjects will be enrolled to receive their assigned dose regimen until disease progression or intolerable toxicity, withdrawal of consent, per Investigator decision, or end of study, whichever occurs first. The maximum treatment duration is 1 year. Subjects who remain on treatment in the absence of disease progression for more than 1 year may continue to receive study drug for the next cycle at the maximum of 2 years.

Conditions

  • Advanced Solid Tumour

Interventions

  • BAT6026Drug

    IV infusions

  • BAT1308Drug

    Ⅳ infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT)Time frame: the first cycle of 21 days for monotherapy and the second cycle of another 21 days for combination therapy
  2. Serious adverse event(SAE)Time frame: Adverse events will be collected from the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St George Private Hospital

    Kogarah, Australia

  • Blacktown Cancer and Haematology Centre

    Sydney, Australia

  • Scientia Clinical Research Limited

    Sydney, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.